Market Overview

JMP Starts Ultragenyx At Outperform, Pipeline Maturity Expected To Continue


In a report published Thursday, JMP Securities analyst Liisa A. Bayko initiated coverage of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) with a Market Outperform rating and a price target of $119.

Analyst Liisa Bayko pointed out that Ultragenyx was a "diversified ultra-orphan disease company with multiple near-term value drivers" and that its shares could continue to rise as "the company's pipeline matures."

"Since its inception in 2010, the company has accumulated an impressive portfolio of four clinical stage assets directed at a half dozen, ultra-rare indications and with $343 million in cash, RARE is well capitalized to execute upon its development plan."

Bayko expects "multiple" product launches through 2016-2018 to take the company into profitability in 2019 and to annual sales of $1.9B in 2023.

Ultragenyx's shares have surged more than 100 percent since the beginning of this year, versus an 18 percent rise in BTK and a 20 percent increase in NBI. The share outperformance of the biotech sector was driven by "a combination of pipeline progress and M&A premium" after the $8B acquisition of Synageva Biopharma Corp (NASDAQ: GEVA).

"We anticipate continued upward momentum as top-line data from several proof-of-concept studies report out over the coming 6-12 months," Bayko said, while adding that there was near-term upside to their model "stemming from the potential for an expedited regulatory path for KRN23 and likely expansion of the clinical stage portfolio, both organically and/or via acquisition."

Latest Ratings for RARE

Feb 2019CitigroupMaintainsNeutralNeutral
Jan 2019Raymond JamesDowngradesMarket OutperformMarket Perform
Nov 2018CitigroupUpgradesSellNeutral

View More Analyst Ratings for RARE
View the Latest Analyst Ratings

Posted-In: JMP SecuritiesAnalyst Color Initiation Analyst Ratings


Related Articles (GEVA + RARE)

View Comments and Join the Discussion!

Latest Ratings

AUPHRaymond JamesMaintains11.0
SRNEB. Riley FBRMaintains12.0
FOXABank of AmericaInitiates Coverage On0.0
AGSCredit SuisseAssumes35.0
CZRCredit SuisseAssumes0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Trader Essentials
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

UBS 'Looking Elsewhere,' Says To Sell Regeneron

EUR/USD Moves Down